Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase

Audio By Carbonatix

TORONTO--(BUSINESS WIRE)--May 14, 2025--

Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in a fireside chat at the virtual Alliance Global Partners Healthcare Company Showcase, taking place May 21, 2025.

Mr. Drysdale’s fireside chat will be webcast live on Wednesday, May 21, 2025, at 1:40 p.m. ET. To listen to the event, please click here to access the webcast. The archived webcast will also be available on the Company’s investor relations website on the Events & Presentations page.

About Cybin

Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions.

With industry leading proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin program, in Phase 3 development for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine program in a Phase 2 study for generalized anxiety disorder. The company also has a research pipeline of investigational, 5-HT-receptor focused compounds.

Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit www.cybin.com or follow the team on X, LinkedIn, YouTube and Instagram.

View source version on businesswire.com:https://www.businesswire.com/news/home/20250514272230/en/

CONTACT: Investor & Media Contact:

Gabriel Fahel

Chief Legal Officer

Cybin Inc.

1-866-292-4601

[email protected]– or –[email protected]

KEYWORD: NORTH AMERICA CANADA

INDUSTRY KEYWORD: ALTERNATIVE MEDICINE MENTAL HEALTH HEALTH NEUROLOGY CLINICAL TRIALS PHARMACEUTICAL BIOTECHNOLOGY

SOURCE: Cybin Inc.

Copyright Business Wire 2025.

PUB: 05/14/2025 07:30 AM/DISC: 05/14/2025 07:29 AM

http://www.businesswire.com/news/home/20250514272230/en